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Abstract
Matrix metalloproteinases (MMPs) play a critical role in cancer pathogenesis, including tumor growth and osteolysis
within the bone marrow microenvironment. However, the anti-tumor effects of MMPs are poorly understood, yet
have significant implications for the therapeutic potential of targeting MMPs. Host derived MMP-7 has previously
been shown to support the growth of bone metastatic breast and prostate cancer. In contrast and underscoring
the complexity of MMP biology, here we identified a tumor-suppressive role for host MMP-7 in the progression of
multiple myeloma in vivo. An increase in tumor burden and osteolytic bone disease was observed in myeloma-bearing
MMP-7 deficient mice, as compared to wild-type controls. We observed that systemic MMP-7 activity was reduced in
tumor-bearing mice and, in patients with multiple myeloma this reduced activity was concomitant with increased
levels of the endogenous MMP inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1). Our studies have identified
an unexpected tumour-suppressive role for host-derived MMP-7 in myeloma bone disease in vivo, and highlight the
importance of elucidating the effect of individual MMPs in a disease-specific context.
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Background
Matrix metalloproteinases (MMPs) are key regulators of
tumor-host interactions due to their ability to alter the
activity of multiple substrates, including growth factors
and cytokines [1]. MMPs have been implicated in the
pathogenesis of many tumors, and increasing evidence
suggests a critical role for host-derived MMPs in cancer
progression [2–6]. As such, MMPs represent an attract-
ive therapeutic target, although to date, clinical trials of
MMP inhibitors have largely been unsuccessful [7]. One
explanation for such failure is likely the broad-spectrum
nature of the inhibitors, leading to a multitude of off
target effects. Therefore, it is necessary to elucidate the
specific mechanisms of individual MMPs in a disease
specific context, in order to develop the most effective
therapeutic strategy.
The bone marrow provides a specialized microenvir-
onment for the development of solid tumor metastases
including breast and prostate cancer, and hematological
malignancies such as multiple myeloma. The reciprocal
relationship between tumor burden and osteolytic bone
disease results in rapid increases in tumor burden and
bone loss. Resultant tumors are generally incurable and
treatments largely palliative [8]. In order to identify new
therapeutic targets and approaches, it is necessary to
elucidate the complex mechanisms that control tumor
growth and survival within the bone marrow micro-
environment. Interactions between tumor cells and cells
of the host bone marrow microenvironment are critical
in both tumor growth and survival, and the development
of the associated bone disease [9]. MMPs have been im-
plicated in these interactions, in particular MMP-7,
which has previously been shown to be highly expressed
within the tumor-bone microenvironment and to pro-
mote breast and prostate cancer osteolysis in vivo [2, 3].
In multiple myeloma, a number of MMPs have been im-
plicated in disease progression, most notably MMP-2
and MMP-9 [10–17]. Indeed, host-derived MMP-9 has
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been shown to promote disease pathogenesis in a
murine model of myeloma in vivo [18]. In vitro studies
suggest that myeloma-derived MMP-7 can activate stro-
mal MMP-2 [17], however the in vivo role of MMP-7 in
myeloma pathogenesis thus far is unknown.
While selective pharmacological inhibition of MMPs
remains a challenge, understanding the biology through
which they mediate their effects can result in the identifica-
tion of novel targetable substrates/pathways. In the present
study, we identified an unexpected tumor-suppressive role
for MMP-7 in myeloma pathogenesis. By combining a
murine model of myeloma with MMP-7 deficient mice,
our results suggest that, in contrast to breast and prostate
cancer bone metastasis, a loss of host-derived MMP-7
increases tumor growth and osteolytic bone disease. Ana-
lysis of patients with multiple myeloma revealed a decrease
in systemic MMP-7 activity in multiple myeloma in vivo.
Taken together, our results identify a novel anti-tumor role
for MMP-7 in vivo and highlight the importance of
elucidating the function of individual MMPs in a
disease-specific context.
Materials and methods
Cell culture and stable cell lines
The 5TGM1-GFP myeloma cell line was cultured as pre-
viously described [19]. 2T3 osteoblasts were cultured in
DMEM supplemented with 10% FCS and L-glutamine.
All cell lines were confirmed as mycoplasma-free. 2T3
osteoblasts were transduced with 105 IFU/ml of lenti-
viral particles from pLenti-suCMV (mMMP-7)-Rsv
(Puro) MMP-7 or null control lentivector (Amsbio).
MMP-7 overexpressed and null transduced cells were
cultured in media as described above and supple-
mented with 5 μg/ml puromycin. Overexpression of
MMP-7 was confirmed by real-time PCR, and cells
were continuously cultured in puromycin to maintain
MMP-7 overexpression.
Animal models
Animal studies were approved by the Vanderbilt University
Institution of Animal Care and Use Committee. Double
null recombinase-activating gene-2 (RAG-2) and MMP-7
mice were generated as previously described [2]. 8 week
old female Rag2−/−;MMP-7−/− (MMP-7−/−) or wild-type
littermate controls (Rag2−/−;MMP-7+/+) were intraven-
ously inoculated with either 106 5TGM1-GFP cells or
vehicle control (PBS). Sera were assayed for monoclonal
mouse IgG2bκ paraprotein as described previously [19].
Tumor burden in bone marrow and spleen was quanti-
tated by flow cytometric analysis of the proportion of
GFP-positive myeloma cells [20]. Myeloma bone disease
was assessed by microCT analysis of trabecular bone
volume and number of osteolytic lesions, as described
previously [20]. Apoptosis and proliferation were assessed
by TUNEL staining and phospho-histone H3 staining re-
spectively, using immunohistochemistry techniques de-
scribed previously [21].
Patient samples
Patient samples were obtained with approval from the
Institutional Review Board and Biospecimen Protocol
Review Group of the Mayo Clinic College of Medicine.
Serum samples from patients with multiple myeloma,
and the respective age- and sex-matched controls, were
obtained through collaboration with M.T.D.
MMP activity
MMP-7 activity in serum was measured using human
or mouse specific MMP-7 activity assays (Quickzyme
Biosciences, Leiden, The Netherlands), according to
the manufacturer’s instructions.
RT-PCR
RNA from cell lines was isolated using the RNeasy kit
(Qiagen). cDNA was generated using the iScript cDNA
Synthesis Kit (BioRad). MMP-7, TIMP-1 and GAPDH
gene expression was quantitated by PCR.
Cell viability
5TGM1-GFP or RPMI 8226 myeloma cells were plated
at 5 × 105 cells/ml and treated with 0–1000 ng/ml
recombinant human active MMP-7 in serum-free media
(Millipore). Proliferation was measured using a colori-
metric CellTiter 96® AQueous Non-Radioactive Cell Pro-
liferation Assay (Promega).
ELISAs and immunoblotting
Serum concentrations of MMP-7 and TIMP1 were mea-
sured according to the manufacturers’ instructions using
commercially available ELISA kits (R&D Systems).
5TGM1-GFP myeloma cells were treated with 100 ng
recombinant mouse galectin-3 (R&D Systems) in the
presence and absence of 10–100 ng MMP-7 and cleav-
age fragments detected by silver staining
Statistics
Statistical significance was determined using a Mann-
Whitney U Test or one-way ANOVA and Tukey-Kramer
posthoc test and considered significant for p < 0.05. In vivo
experiments were repeated on a minimum of two separate
occasions and in vitro experiments were performed a
minimum of three separate occasions. Data are repre-
sented as mean ± SE unless otherwise stated.
Results
Previously, host derived MMP-7 has been shown to pro-
mote the growth of bone metastatic breast and prostate
cancer. To determine the role of host-derived MMP-7 in
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myeloma pathogenesis, we used immunocompromized
(RAG-2−/−) mice that were wild type or null for MMP-7
and can be successfully engrafted with the 5T myeloma
model [18]. The 5T model is well-characterized and
closely mimics human myeloma, however 5T myeloma
cells will only grow in syngeneic C57BL/KaLwRij mice,
bg/nu/Xid mice or Rag2−/− mice [18]. Littermate wild-
type (WT, Rag2−/−;MMP-7+/+) and MMP-7 homozygous
deficient (MMP-7−/−, Rag2−/−; MMP-7−/−) mice were
inoculated with 5TGM1 myeloma cells. A significant
increase in tumor burden in myeloma-bearing MMP-
7−/− mice was demonstrated by an increase in
myeloma-specific IgG2bκ serum concentrations and
GFP-positive myeloma cells in the bone marrow and
spleen, as compared to myeloma-bearing WT mice
(Fig. 1a and b). Subsequent histological assessment of the
bone marrow demonstrated that the proliferative rate of
myeloma cells within the MMP-7−/− environment was
greater than that in WTanimals (Fig. 1c). A significant de-
crease in myeloma cell apoptosis was also observed in
myeloma-bearing MMP-7−/−mice as compared with WT
mice (Fig. 1d). Accompanying the increase in tumor bur-
den, myeloma-bearing MMP-7−/− mice developed a more
severe osteolytic bone disease, with decreased trabecular
bone volume (Fig. 2a) and an increase in osteolytic lesions
(Fig. 2b) as compared with myeloma-bearing WT mice.
Myeloma-bearing mice demonstrated a significant in-
crease in osteoclast number and decrease in osteoblast
number (Fig. 2c-d).
Further support for a role for MMP-7 in myeloma
pathogenesis was provided by a significant reduction in
MMP-7 activity in serum of myeloma-bearing mice as
compared to non-tumor controls (Fig. 3a). The 5T
model of myeloma has a number of well-characterized
similarities with human myeloma. In order to determine
whether the role of MMP-7 in murine myeloma patho-
genesis translated to the clinical setting, we measured
the concentration and activity of MMP-7 in newly diag-
nosed multiple myeloma patients. Patient samples were
age-, sex- and BMI-matched to normal controls. A
significant reduction in MMP-7 activity was detected
following an MMP-7 substrate-based activity assay
(Fig. 3b). In contrast to this reduction in activity levels,
no difference was detected in the serum concentrations
of MMP-7 (Fig. 3c).
Since MMP-7 activity is decreased in myeloma in vivo,
both in patients with multiple myeloma and in a murine
model of myeloma, we sought to determine whether the
endogenous MMP inhibitors were elevated in these sam-
ples. Of the four TIMP family members, TIMP-1 is the
most effective inhibitor of MMP-7 [22]. RT-PCR analysis
revealed that 5TGM1 cells and osteoblasts express
A B
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Fig. 1 Myeloma tumor burden is increased in MMP-7-deficient mice. Wild-type (WT) or MMP-7 homozygous deficient (MMP-7−/−) mice were inoculated
with 5TGM1 myeloma cells (MM) or vehicle control. Tumor burden was measured by (a) serum IgG2bκ concentrations and (b) flow cytometric analysis
of GFP-positive myeloma cells in the bone marrow and spleen. c Myeloma cell proliferation in the bone marrow was quantitated by phospho-histone
H3 staining, (d) Myeloma cell apoptosis was quantitated by TUNEL staining. Data represent mean ± SEM. Mann Whitney U test *p < 0.05,
**p < 0.01, ***p < 0.001 as compared to WT + MM. (WT, n = 7; MMP-7−/−, n = 4; WT + MM, n = 8; MMP-7−/− + MM, n = 5)
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Fig. 2 Osteolytic bone disease is increased in myeloma-bearing MMP-7-deficient mice. Wild-type (WT) or MMP-7 homozygous deficient (MMP-7
−/−) mice were inoculated with 5TGM1 myeloma cells (MM) or vehicle control. MicroCT analysis demonstrated that trabecular bone volume was
decreased (a) and osteolytic lesions were increased (b) in myeloma bearing MMP-7−/− mice, as compared to myeloma bearing WT mice.
Histomorphometric analysis demonstrated an increase in osteoclasts (c) and a decrease in osteoblasts (d) in myeloma-bearing WT and
MMP-7−/− mice as compared to control. Data represent mean ± SEM. Mann Whitney U test *p < 0.05, **p < 0.01, ***p < 0.001 (WT, n = 7;




Fig. 3 MMP7 activity is decreased in the serum of myeloma-bearing mice or patients with multiple myeloma. Analysis of MMP7 activity in the
serum of myeloma-bearing mice (a) or control and myeloma patients (b) was detected using an MMP7 activity assay. c MMP7 concentration in
serum of control and myeloma patients, as measured by ELISA. An increase in the serum concentration of TIMP-1 was detected by ELISA in
myeloma-bearing mice (d) and patients with multiple myeloma (e). Data are presented as mean. Mice; control n = 5; MM n = 6. Patients; control,
n = 16; MM, n = 16. ns = not significant. Statistical analysis by Mann Whitney U test
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TIMP-1 and we observed significantly higher levels of
TIMP-1 in serum derived from multiple myeloma bear-
ing animals compared to control (Fig. 3d). In keeping
with this observation, we also found that serum from
human multiple myeloma patients contained signifi-
cantly higher levels of TIMP-1 compared to healthy con-
trols (Fig. 3e).
The significant increase in both tumor burden and the
associated osteolytic bone disease in MMP-7−/− mice
suggest that host-derived MMP-7 plays a specific tumor-
suppressive role in myeloma. Myeloma cells were not
found to express MMP-7, but instead expressed high
concentrations of the endogenous MMP inhibitor
TIMP-1 (Fig. 4a-b). Treatment of murine and human
myeloma cells with increasing concentrations of recom-
binant MMP-7 in serum-free media had a limited effect
to reduce cell viability, that was not dose-dependent
(Fig. 4c-d). Similarly, flow cytometric analysis of apop-
tosis revealed no significant increase in apoptosis or
necrosis following treatment with MMP-7, and western
blot analysis confirmed no significant increase in cleaved
caspase-3 or cleaved PARP (data not shown). Confirm-
ation of functional MMP-7 activity was demonstrated by
cleavage of the substrate galectin-3 (Fig. 4e). To begin to
determine whether the tumour suppressive effect of
MMP7 may be mediated via cells of the host microenvir-
onment, myeloma cells were cultured in the presence of
2T3 preosteoblasts. This resulted in an increase in mye-
loma cell viability that was prevented by overexpression
of MMP-7 in preosteoblasts (Fig. 4f ).
Conclusions
The present study identifies an unexpected role for
MMP-7 in myeloma pathogenesis, with a striking in-
crease in myeloma tumor burden and osteolytic bone
disease in myeloma-bearing MMP-7 deficient mice, as
compared to wild-type controls. These in vivo murine
myeloma studies are supported by clinical evidence
demonstrating a significant reduction in MMP-7 activity
in patients with multiple myeloma. These studies dem-
onstrate that host-derived MMP-7 plays a suppressive
role in myeloma pathogenesis.
The increase in myeloma tumor burden in response to
a loss of host-derived MMP-7 is in distinct contrast to
previous studies in prostate cancer and breast cancer
osteolysis, where tumor burden and osteolytic bone dis-
ease were decreased in MMP-7 deficient mice [2, 3].




Fig. 4 MMP-7 has limited effects on MMP-7 viability. a MMP-7 mRNA was measured in 2T3 osteoblasts and 5TGM1 myeloma cells. b TIMP-1 mRNA was
measured in 2T3 osteoblasts, 14M1 myeloma-associated bone marrow stromal cells, ST2 bone marrow stromal cells and 5TGM1 myeloma cells. Treatment
of 5TGM1 (c) or RPMI 8226 (d) myeloma cells with recombinant MMP-7 had limited effects on cell viability (n = 3). e Recombinant MMP7 can cleave
murine galectin-3 into distinct fragments. 100 ng galectin-3 was incubated with increasing concentrations of MMP-7 (10–100 ng) and cleavage
fragments detected by silver staining. f Over-expression of MMP-7 in 2 T3 osteoblasts decreased myeloma cell viability in a coculture of
myeloma cells and osteoblasts (n = 3). Data represent mean ± SEM. Statistical analysis by one-way ANOVA and Tukey-Kramer posthoc test
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of cleaving RANKL to a soluble active form [2]. In mur-
ine models of prostate and breast cancer osteolysis,
MMP-7 deficiency was associated with a reduction in
the cleavage of RANKL to a soluble form and a decrease
in osteoclasts at the tumor:bone interface [2, 3]. How-
ever, in the present study, no significant difference in
RANKL was detected in myeloma-bearing MMP-7 defi-
cient mice as compared to wild-type controls (data not
shown). Notably, RANKL has been implicated in the
pathogenesis of myeloma bone disease, in addition to
that of breast and prostate cancer, although anti-RANKL
is currently only approved for the treatment of solid
tumor metastases [8]. The present study suggests a
distinct difference in the response of myeloma to host-
derived MMP-7, as compared to breast and prostate
cancer. Although there are many similarities in cellular
and molecular mechanisms of tumor growth and bone
disease between myeloma and solid tumor bone metas-
tases, there are also numerous examples of differences,
including the relative contributions of PTHrP and Dkk1
[23–27]. However, there are limited examples of such
opposing responses observed between the tumor types,
highlighting the importance of studying MMP function
in specific disease contexts.
To date, myeloma cells have been reported to express
a number of MMPs, which are postulated to promote
numerous aspects of tumor growth and osteolytic bone
disease. MMP-2 and MMP-9 are the most widely studied
and reported, with evidence for key roles in angiogenesis,
tumor growth and extracellular matrix remodeling
[10, 11, 14–16]. The contributions of host-derived
MMPs to disease pathogenesis are poorly studied, due
largely to difficulties in studying the host microenvir-
onment in vivo. We have previously shown that mye-
loma tumor burden is decreased in MMP-9 deficient
mice, supporting a key role for host-derived MMP-9
in myeloma pathogenesis [18]. In contrast, the role of
MMP-7 is relatively unknown in myeloma, and is cur-
rently limited to the expression of MMP-7 by human
myeloma cells, with resultant in vitro activation of
MMP-2 [17]. In the present study, we have identified
host-derived MMP-7 as having a tumor-suppressive
role in myeloma. While the majority of MMPs pro-
mote tumor progression, inhibitory roles for MMPs
have also been reported, including that of MMP-8 in
oral cancer and lymph node metastasis [28–30]. In
support of disease specific effects of MMP-s, MMP-3
is known to promote breast cancer progression but
protect against the progression of squamous cell car-
cinoma [31–33]. As shown here, MMP-7 activity was
reduced in the serum of both myeloma-bearing mice
and in patients with multiple myeloma. Of note, no
significant difference in MMP-7 concentration was
detected, demonstrating the importance of studying
enzymatic activity when investigating MMP regula-
tion. An increase in the endogenous MMP inhibitor
TIMP-1 was detected in patients with multiple myeloma,
which may account for the reduction in MMP-7 activity,
although it is likely that other mechanisms also
contribute.
Genetic ablation of individual MMPs can result in the
enhanced expression of other MMP family members
with overlapping substrate specificity [34]. For example,
previous reports with MMP-7 deficient mice have identi-
fied increased expression MMP-2 [35]. This indicates
the potential for compensatory mechanisms in regards
to the cleavage of substrates by other MMPs in our sys-
tem [36]. However, the data suggests that the increased
expression of MMPs is insufficient to rescue the effects
of MMP-7 implying that the spatial and temporal ex-
pression of individual MMPs is important. We have pre-
viously shown for example that MMP-7 and MMP-9
expression from osteoclasts have distinct roles in the
context of bone metastatic breast cancer [3].
MMP-7 has a number of reported substrates, includ-
ing some associated with myeloma cell apoptosis such as
FASL [37, 38]. However, cleavage of these substrates
would be predicted to decrease their anti-tumor effect,
rendering them unlikely candidates to explain the anti-
myeloma effect of MMP-7 in the present study. Mye-
loma cells were not found to express MMP-7, and had a
limited, inconsistent response to treatment with re-
combinant MMP-7 in vitro. This suggests that the
myeloma-suppressive effect of MMP-7 is not merely a
direct anti-tumour effect, but likely a complex mech-
anism involving cleavage of multiple substrates within
the tumour-bone microenvironment. In support of
this, the ability of preosteoblasts to promote myeloma
cell viability was reduced in the presence of excess
MMP-7 expressed by the host cells, highlighting the
tumour-suppressive effect of MMP-7 in the myeloma-
bone microenvironment and suggesting that the effect
may be mediated at least in part by a substrate
expressed by osteoblasts.
Despite many recent therapeutic advances, myeloma
remains a fatal malignancy, in part due to its symbiotic
relationship with the bone marrow microenvironment.
Therefore, it is imperative to identify both tumor-
derived and host-derived factors that contribute to dis-
ease pathogenesis. MMP-7 represents one such factor
that is highly expressed within this specialized niche.
Our studies have collectively identified an unexpected
role for MMP-7 in myeloma pathogenesis, whereby a
loss of MMP-7 promotes tumor growth and myeloma
bone disease. MMPs represent attractive therapeutic tar-
gets for the treatment of many malignancies. However
the failure of initial clinical trials using broad-spectrum
MMP inhibitors reveals the complexity of MMPs as
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targets. The current study clearly demonstrates that
inhibition of MMP-7 is an inappropriate approach for
the treatment of myeloma and its associated bone
disease. This is in direct contrast to breast and prostate
cancer bone metastases, and highlights the necessity to
elucidate the differential roles of individual MMPs in
disease specific contexts.
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